Epstein-Barr病毒阳性B细胞淋巴瘤在体内对MDM2抑制剂高度敏感
研究在免疫缺陷小鼠中建立EBV阳性B细胞淋巴瘤模型,评估MDM2抑制剂navtemadlin和idasanutlin的体内活性。全部5例EBV阳性异种移植相关B细胞淋巴瘤经navtemadlin或idasanutlin治疗均观察到肿瘤消退,navtemadlin还使2例移植后淋巴增殖性疾病幼年患者的EBV阳性淋巴瘤消退并阻止全身播散。
要点
- 全部5例EBV阳性异种移植相关B细胞淋巴瘤经navtemadlin或idasanutlin治疗均观察到肿瘤消退。
- MDM2抑制剂治疗激活p53通路并下调细胞周期效应分子。
- navtemadlin使2例移植后淋巴增殖性疾病患者的EBV阳性淋巴瘤消退并阻止全身播散。
核心结论
- 结果为MDM2抑制剂靶向治疗EBV阳性淋巴瘤提供概念验证,并支持利用EBV感染或BCL6表达缺失识别MDM2抑制剂应答者。
研究设计与样本
- 在免疫缺陷小鼠中建立EBV阳性B细胞淋巴瘤模型,评估MDM2抑制剂navtemadlin和idasanutlin的体内活性。
- 对人淋巴瘤细胞系(EBV阳性或BCL6表达不可检出)进行分子特征分析。
- 使用源自2例移植后淋巴增殖性疾病幼年患者的EBV阳性淋巴瘤进行navtemadlin治疗评估。
主要发现
- 全部5例EBV阳性异种移植相关B细胞淋巴瘤经navtemadlin或idasanutlin治疗均观察到肿瘤消退。
- MDM2抑制剂治疗在人淋巴瘤细胞系中激活p53通路并下调细胞周期效应分子,这些细胞系为EBV阳性或BCL6表达不可检出。
- navtemadlin治疗使源自2例移植后淋巴增殖性疾病幼年患者的EBV阳性淋巴瘤消退并阻止全身播散,其中1例肿瘤对病毒特异性T细胞治疗耐药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epstein-Barr virus-positive (EBV-positive) B-cell lymphomas are common in immunocompromised patients and remain an unmet medical need. Here we report that MDM2 inhibitors (MDM2is) navtemadlin and idasanutlin have potent in vivo activity in EBV-positive B-cell lymphoma established in immunocompromised mice. Tumor regression was observed in all 5 EBV-positive xenograft-associated B-cell lymphomas treated with navtemadlin or idasanutlin. Molecular characterization showed that treatment with MDM2is resulted in activation of p53 pathways and downregulation of cell cycle effectors in human lymphoma cell lines that were either EBV-positive or had undetectable expression of BCL6, a transcriptional inhibitor of the TP53 gene. Moreover, treatment with navtemadlin resulted in tumor regression and prevented systemic dissemination of EBV-positive lymphoma derived from 2 juvenile patients with posttransplant lymphoproliferative diseases, including 1 whose tumor was resistant to virus-specific T-cell therapy. These results provide proof-of-concept for targeted therapy of EBV-positive lymphoma with MDM2is and the feasibility of using EBV infection or loss of BCL6 expression to identify responders to MDM2is.
引用
- Zhang X, Zhang R, Ren C, et al. Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Adv. 2022. PMID: 34861697. doi:10.1182/bloodadvances.2021006156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。